+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 60Years
All Genders
ID06969170

Phase 2a Trial to Evaluate Safety and Effects of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder

Led by Claudio N Soares · Updated on 2026-08-12

50

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and initial effectiveness of a 3 mg dose of psilocybin oral solution in adults diagnosed with Generalized Anxiety Disorder GAD. This Phase 2a clinical trial involves participants aged 18 to 60 who have a moderate to severe level of anxiety as measured by the Hamilton Anxiety Rating Scale HAM-A and the GAD-7 scale. The study is sponsored by Claudio N Soares and explores how psilocybin might affect anxiety symptoms compared to a placebo. The study includes three phases a Screening Phase lasting up to 4 weeks where eligibility is confirmed through medical and psychiatric assessments a 4-week Open-label Run-in Phase where all participants receive daily psilocybin oral solution with weekly clinic visits and remote contacts and a 4-week Double-blind Treatment Phase where participants showing significant improvement are randomly assigned to receive either psilocybin or a placebo daily. Throughout the study, participants undergo cognitive tests, EEGs, and report on their symptoms and safety. Participants will be closely monitored with safety assessments, cognitive evaluations, and patient-reported outcomes at various timepoints during the Open-label and Double-blind phases. After completing the treatment phases, a 2-week End of Treatment period is included to further assess safety and participant experience. The primary outcome focuses on safety and tolerability from enrollment through the end of treatment, while secondary outcomes measure changes in anxiety symptoms. Total participation may last approximately 14 weeks.

CONDITIONS

Brief Title

Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder

Research Team

C

Claudio N Soares, MD, PhD, FRCPC, MBA

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here